April 2010
Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p4
Trade Publication
The article reports on the acquisition of the rights to a series of pre-clinical compounds by Transition Therapeutics from Eli Lilly and Company in the area of diabetes. Under the deal, Transition Therapeutics will have exclusive worldwide rights to develop and potentially commercialize a class of compounds that provides glycemic control and other beneficial effects including weight loss. The partnership covers the gastrin-based therapies as potential diabetes disease-modifying agents.


Related Articles

  • Transition Could Get $130M in Diabetes Deal With Lilly. Hollingsworth, Catherine // BioWorld Today;3/17/2008, Vol. 19 Issue 52, p1 

    The article reports on the possibility that Transition Therapeutics Inc. will receive up to $137 million in a deal with drug company Eli Lilly and Co., which will acquire the rights to the company's gastrin-based therapies for diabetes. Under the deal, Transition will receive $7 million in an...

  • Transition Could Get $130M in Deal With Lilly.  // Bioworld Week;3/24/2008, Vol. 16 Issue 12, p2 

    The article reports on the money received by Transition Therapeutics Inc. in a deal with Eli Lilly & Co., which will acquire rights to Transition's gastrin-based therapies for diabetes in the U.S. Under the agreement, Transition will receive $7 million in an up-front payment and up to $130...

  • Lilly African effort boosts good will, not bottom line. Postman, Lore // Indianapolis Business Journal;6/12/95, Vol. 16 Issue 11, p4A 

    Reports that a research commitment by Eli Lilly and Co. to improve diabetes treatment in Ghana will promote good will but will not increase the company's international profits. Amount of financial support for research program; Estimated number of Ghanaians suffering from diabetes who receive...

  • Eli Lilly shifts spotlight to diabetes pipeline. Wall, J. K. // Indianapolis Business Journal;5/14/2012, Vol. 33 Issue 11, p9 

    The article reports on greater profits sighted by Eli Lilly and Co. to its Tradjenta Tablets for diabetes treatment.

  • Lilly's Trulicity Ships To U.S. Pharmacies.  // Chain Drug Review;11/24/2014, Vol. 36 Issue 19, p62 

    The article reports that Eli Lilly & Co. has rolled out Trulicity, a onceweekly treatment for type 2 diabetes, to U.S. pharmacies.

  • Mass production of insulin. McLaughlin, Kathleen // Indianapolis Business Journal;6/1/2015, Vol. 36 Issue 14, p20 

    The article discusses the mass production of insulin for diabetes treatment by pharmaceutical company Eli Lilly and Co. in 1923

  • MacroGenics Looks to Pipeline After Teplizumab Miss.  // Bioworld Week;10/25/2010, Vol. 18 Issue 43, p4 

    The article reports on the agreement between MacroGenics Inc. and its partner Eli Lilly and Co. to dig deeper into the data of their Type 1 diabetes after it failed to meet the efficacy endpoint.

  • FDA approves Eli Lilly's Basaglar long-acting insulin.  // Chain Drug Review;1/4/2016, Vol. 38 Issue 1, p107 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Basaglar insulin glargine product to treat diabetes.

  • Biodel Takes Big Hit on Diabetes Data Unknowns.  // Bioworld Week;9/15/2008, Vol. 16 Issue 37, p2 

    The article reports on the issues concerning Biodel Inc.'s Phase III trials of diabetes treatment VIAject in Danbury, Connecticut. The company says that VIAject met the studies' objective of noninferiority to Eli Lilly and Co.'s Humulin insulin injection. However, Wall Street analysts seemed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics